Table 11.
Result of success factors of new drug clinical trials (Phase 4—NME vs. Biologicals)
| Variable | NME (Phase 4) | Biologicals (Phase 4) | ||||||
|---|---|---|---|---|---|---|---|---|
| Model 1 | Model 2 | Model 3 | Model 4 | Model 1 | Model 2 | Model 3 | Model 4 | |
| Experience |
1.000 (0.000) |
1.000 (0.000) |
1.000 (0.000) |
1.000 (0.000) |
1.000 (0.001) |
1.000 (0.001) |
1.000 (0.001) |
1.000 (0.001) |
| Success ratio |
47.776*** (16.638) |
45.963*** (15.862) |
46.676*** (15.834) |
47.128*** (15.968) |
53.885 (99.519) |
38.034 (55.944) |
41.296 (60.675) |
31.627 (46.973) |
| Duration |
1.000 (0.000) |
1.000 (0.000) |
1.000 (0.000) |
1.000 (0.000) |
0.999 (0.000) |
0.999 (0.000) |
0.999 (0.000) |
0.999 (0.001) |
| Relationship type |
0.928 (0.234) |
1.118 (0.220) |
0.427 (0.613) |
0.971 (0.767) |
||||
| Nation |
1.372 (0.679) |
1.423 (0.364) |
2.300 (4.030) |
1.720 (1.447) |
||||
| Continent |
1.146 (0.589) |
1.461 (0.429) |
2.081 (2.902) |
2.497 (2.442) |
||||
| N | 1511 | 1511 | 1511 | 1511 | 219 | 219 | 219 | 219 |
| Pseudo-R2 | 0.1448 | 0.1432 | 0.1446 | 0.177 | 0.1129 | 0.1188 | 0.1241 | |
| Prob > χ2 | 0.000 | 0.000 | 0.000 | 0.1302 | 0.101 | 0.086 | 0.074 | |
| Log-likelihood | − 452.757 | − 453.581 | − 452.838 | − 29.861 | − 30.453 | − 30.252 | − 30.070 | |
***p < 0.01, **p < 0.05, *p < 0.1